CTN-0075: Physician-Pharmacist Collaboration in the Management of Patients with Opioid Use Disorder (Pharm-OUD-Care)
Li-Tzy Wu, ScD, RN
Duke Clinical Research Institute
This study will test feasibility of transitioning office-based buprenorphine treatment of adult patients with opioid use disorders from physician to coordinated physician-pharmacist care management in order to inform the design of a future randomized clinical trial.
A collaborative care model for people with opioid use disorder that involves buprenorphine-waivered physicians and community pharmacists appears to be feasible to operate in the United States and have high acceptability to patients. A high proportion (93.4%, 71/76) of eligible participants enrolled into the study. There were high rates of treatment retention (88.7%) and adherence (95.3%) at the end of the study. The proportion of opioid-positive urine drug screens (UDSs) among complete cases (i.e. those with all six UDSs collected during 6 months) at month 6 was (4.9%, 3/61). Intervention fidelity was excellent. Pharmacists used PDMP at 96.8% of visits. There were no opioid-related safety events. Over 90% of patients endorsed that they were “very satisfied with their experience and the quality of treatment offered,” that “treatment transfer from physician’s office to the pharmacy was not difficult at all,” and that “holding buprenorphine visits at the same place the medication is dispensed was very or extremely useful/convenient.” Similarly, positive ratings of satisfaction were found among physicians/pharmacists.
Primary Outcomes Article: Wu L, et al. Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients with Opioid Use Disorder: Results from a Multisite Study of the National Drug Abuse Treatment Clinical Trials Network. Addiction 2021 (in press). [get article]
All Participating Nodes: